Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec

NCT01865279 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions

DRUG: insulin degludec
DRUG: placebo
DRUG: insulin degludec
DRUG: isophane human insulin

Sponsor

Novo Nordisk A/S